Technology

Dark Antigens® EDAPT® EnTiCE®

Shining a light on the untapped 98% of the genome

Only 2% of our DNA encodes the proteins that have defined modern drug discovery; the remaining 98%, the dark genome, is a vast untapped source of cancer-specific antigens.

With our unrivaled platform for discovery and validation of these antigens, Enara Bio is delivering a pipeline of first-in-class immunotherapies to bring transformative benefit to cancer patients.